Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells
Status:
Completed
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
This is a multicentre, single-arm study of nilotinib 300 mg BID in newly diagnosed patients
with CP-CML. This study is designed to establish the disappearance of Ph+ stem cells
(CD34+/lin-) in BM during nilotinib treatment.
In addition, in this study the investigators aim to perform Gene Expression Profiling (GEP)
of CML enrolled patients using Affymetrix GeneChip Instruments and Software Systems, and
Affymetrix GeneChip Human Genome U133 Plus 2.0 (whole human transcriptome analysis) at
diagnosis and at 3 different time points during treatment with Nilotinib (after 3, 6, 12
months).